ILMN

Business Context and Reporting Period

Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 27, 2004
Business Overview: Illumina develops tools for large-scale genetic analysis, including SNP genotyping systems (BeadLab, BeadStation), oligonucleotides, and genotyping services. The company is in a growth phase, commercializing new products while managing significant legal disputes and operating losses.

Key Financial Metrics

Margins: Gross margin on product and service revenue was 72% for both the three and six months ended June 27, 2004, an improvement from 52% and 47% in the comparable 2003 periods.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 141% year-over-year for the six-month period ($22.3M vs. $9.0M). Product revenue surged 335% ($18.0M vs. $4.1M) driven by sales of BeadStation systems and consumables. Service revenue declined slightly ($3.0M vs. $3.3M) due to fewer third-party contracts.
• Profitability Improvement: Net loss narrowed significantly to $7.4M for the six months ended June 27, 2004, compared to $17.6M in the prior year period. This was driven by revenue growth and reduced R&D expenses.
• Liquidity Expansion: Cash and cash equivalents increased from $12.5M at year-end 2003 to $54.0M at June 27, 2004. This increase was primarily due to $29.5M in proceeds from the issuance of common stock in May 2004.
• Expense Trends: R&D expenses decreased 12% year-over-year ($10.5M vs. $11.9M) as development of key products launched in 2003 was completed. SG&A expenses increased 35% ($11.7M vs. $8.7M) due to expanded sales and marketing efforts.

Guidance, Outlook, Risks, and Contingencies

Outlook: Management expects to continue incurring net losses through at least the end of 2004. Operating expenses are expected to increase as the company expands sales infrastructure. The company believes current cash, investments, and grant funding are sufficient to fund operations for at least 24 months.

Material Risks and Contingencies:

• Applied Biosystems Litigation: A complex dispute involving patent infringement and breach of contract. Applied Biosystems seeks damages exceeding $60 million and an injunction. Arbitration is scheduled for completion in December 2004. Illumina has not accrued for potential losses but notes a $10.0M advance payment from Applied Biosystems could offset adverse outcomes up to that amount.
• Employment Lawsuit Judgment: A $7.7M judgment from a 2002 termination-of-employment lawsuit is on appeal. Illumina has posted a $11.3M surety bond, restricting approximately $12.5M in marketable securities as collateral until the appeal is resolved.
• Affymetrix Litigation: In July 2004, Affymetrix filed a patent infringement suit alleging Illumina products infringe six patents. Illumina intends to defend vigorously.
• Real Estate Transaction: Illumina entered a conditional agreement to sell its land and buildings for $42.0M and lease them back. The transaction is subject to closing conditions, including the buyer's IPO, and is not guaranteed.

Investor Verification Checklist

• Cash Position vs. Restricted Assets: Verify the distinction between the $54M in liquid cash and the $12.2M in restricted cash/investments held as collateral for the employment lawsuit appeal.
• Revenue Concentration: Assess reliance on large, infrequent transactions (e.g., BeadLab systems, HapMap Project grants) which cause significant quarter-to-quarter revenue volatility.
• Legal Exposure: Monitor the status of the Applied Biosystems arbitration (decision expected early 2005) and the Affymetrix lawsuit, as adverse rulings could result in injunctions or significant cash payouts.
• Real Estate Sale: Confirm the status of the conditional sale-leaseback agreement for the San Diego facility, which is a potential source of $16M in additional cash but remains uncertain.
• Burn Rate: Evaluate the trajectory of operating expenses, particularly SG&A, against revenue growth to determine the timeline to profitability.